250 related articles for article (PubMed ID: 36240167)
1. Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain.
Clarke S; Butcher BE; McLachlan AJ; Henson JD; Rutolo D; Hall S; Vitetta L
PLoS One; 2022; 17(10):e0270543. PubMed ID: 36240167
[TBL] [Abstract][Full Text] [Related]
2. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
[TBL] [Abstract][Full Text] [Related]
3. A pilot safety, tolerability and pharmacokinetic study of an oro-buccal administered cannabidiol-dominant anti-inflammatory formulation in healthy individuals: a randomized placebo-controlled single-blinded study.
Vitetta L; Butcher B; Henson JD; Rutolo D; Hall S
Inflammopharmacology; 2021 Oct; 29(5):1361-1370. PubMed ID: 34357480
[TBL] [Abstract][Full Text] [Related]
4. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
[TBL] [Abstract][Full Text] [Related]
5. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and Efficacy of a 10:25 Preparation of Δ9-Tetrahydrocannabinol and Cannabidiol for Treatment of Chronic Back or Neck Pain: A Multiple-Dose Escalation Study.
Glare P; Chye R; Bloch M; Arya M; Moore A; Montgomery J
Med Cannabis Cannabinoids; 2023; 6(1):66-76. PubMed ID: 37465637
[TBL] [Abstract][Full Text] [Related]
7. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
[TBL] [Abstract][Full Text] [Related]
8. Cannabis-based medicines for chronic neuropathic pain in adults.
Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of escalating cannabinoid doses in healthy cats.
Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
[TBL] [Abstract][Full Text] [Related]
10. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
11. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.
Johnson JR; Burnell-Nugent M; Lossignol D; Ganae-Motan ED; Potts R; Fallon MT
J Pain Symptom Manage; 2010 Feb; 39(2):167-79. PubMed ID: 19896326
[TBL] [Abstract][Full Text] [Related]
12. Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model: A Pilot Study.
Stauch CM; Ammerman B; Sepulveda D; Aynardi MC; Garner MR; Lewis G; Morgan D; Dhawan A
Am J Sports Med; 2021 Jul; 49(9):2522-2527. PubMed ID: 34097540
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal Actions of the Cannabis Constituents Δ(9)-Tetrahydrocannabinol and Cannabidiol in a Mouse Neuropathic Pain Model.
Casey SL; Mitchell VA; Sokolaj EE; Winters BL; Vaughan CW
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955774
[TBL] [Abstract][Full Text] [Related]
14. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
[TBL] [Abstract][Full Text] [Related]
15. A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome.
Abi-Jaoude E; Bhikram T; Parveen F; Levenbach J; Lafreniere-Roula M; Sandor P
Cannabis Cannabinoid Res; 2023 Oct; 8(5):835-845. PubMed ID: 36040329
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
Peters EN; MacNair L; Mosesova I; Christians U; Sempio C; Klawitter J; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
Eur J Clin Pharmacol; 2022 Feb; 78(2):259-265. PubMed ID: 34664109
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.
Moore CF; Weerts EM
Psychopharmacology (Berl); 2022 May; 239(5):1397-1408. PubMed ID: 34652500
[TBL] [Abstract][Full Text] [Related]
18. A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.
Bergeria CL; Strickland JC; Spindle TR; Kalaba M; Satyavolu PU; Feldner M; Vandrey R; Bonn-Miller M; Peters EN; Weerts E
Exp Clin Psychopharmacol; 2023 Apr; 31(2):312-317. PubMed ID: 35467921
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
20. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
